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Abstract
Historically, non–small‐cell lung cancer (NSCLC) patients who are non‐white, have 
low incomes, low educational attainment, and non‐private insurance have worse sur-
vival. We assessed whether differences in survival were attributable to sociodemo-
graphic factors, clinical characteristics at diagnosis, or treatments received. We 
surveyed a multiregional cohort of patients diagnosed with NSCLC from 2003 to 
2005 and followed through 2012. We used Cox proportional hazard analyses to esti-
mate the risk of death associated with race/ethnicity, annual income, educational at-
tainment, and insurance status, unadjusted and sequentially adjusting for 
sociodemographic factors, clinical characteristics, and receipt of surgery, chemo-
therapy, and radiotherapy. Of 3250 patients, 64% were white, 16% black, 7% 
Hispanic, and 7% Asian; 36% of patients had incomes <$20 000/y; 23% had not 
completed high school; and 74% had non‐private insurance. In unadjusted analyses, 
black race, Hispanic ethnicity, income <$60 000/y, not attending college, and not 
having private insurance were all associated with an increased risk of mortality. 
Black‐white differences were not statistically significant after adjustment for soci-
odemographic factors, although patients with patients without a high school diploma 
and patients with incomes <$40 000/y continued to have an increased risk of mortal-
ity. Differences by educational attainment were not statistically significant after ad-
justment for clinical characteristics. Differences by income were not statistically 
significant after adjustment for clinical characteristics and treatments. Clinical char-
acteristics and treatments received primarily contributed to mortality disparities by 
race/ethnicity and socioeconomic status in patients with NSCLC. Additional efforts 
are needed to assure timely diagnosis and use of effective treatment to lessen these 
disparities.
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1 |  INTRODUCTION
Lung cancer is the leading cause of cancer‐related death in 
the United States. While comprising 14% of new cancer diag-
noses, lung cancer accounts for 27% of cancer‐related deaths 
every year.1 Nearly 90% of lung cancer patients are diagnosed 
with non–small‐cell lung cancer (NSCLC), and most of these 
patients are diagnosed at advanced stages; only 21% survive 
more than 5 years.2
Numerous studies have documented disparities in sur-
vival among patients diagnosed with NSCLC. In partic-
ular, patients who are non‐white,3-5 low income,6,7 insured 
by Medicaid,8 or uninsured9-11 have a higher mortality rate 
from NSCLC compared with other patients. However, it is 
unclear how clinical and treatment differences contribute 
to these survival differences. Racial/ethnic minorities are 
more likely than white patients to be diagnosed at advanced 
stages,12 have a greater number of medical comorbidities,13 
and receive fewer appropriate treatments,3,14-17 all of which 
may contribute to increased mortality. Similarly, patients in-
sured by Medicaid are diagnosed at a later stage and receive 
fewer appropriate treatments than patients with private insur-
ance.7,18 Lower income patients are less likely than higher 
income patients to receive curative treatments; they also have 
a poorer prognosis.19
Many of the studies examining survival disparities in 
patients with NSCLC are single‐center cohort studies that 
may not be generalizable or registry studies that lack indi-
vidual‐level data. The Cancer Care Outcomes Research and 
Surveillance (CanCORS) study is a large multiregional ob-
servational study of newly diagnosed lung and colorectal 
cancer patients that offers the opportunity to avoid these 
shortcomings. Previous studies using this dataset have ex-
amined racial/ethnic differences in depressive symptoms,20 
health‐related quality of life,21 and perceived an unmet need 
for supportive services22 among patients with lung cancer, 
but these have not examined differences in survival. In this 
study, we use the CanCORS dataset to better understand the 
factors contributing to survival differences in patients newly 
diagnosed with NSCLC.
2 |  METHODS
2.1 | Data overview
Details of the CanCORS study design have been described 
elsewhere.23 Briefly, patients newly diagnosed with colo-
rectal or lung cancer were enrolled at study sites across the 
country from 2003 to 2005. The sites include 5 geographi-
cally defined areas (Iowa, Alabama, and certain counties 
in California and North Carolina), 5 integrated healthcare 
systems, and 15 Veterans Affairs medical centers. Eligible 
patients were identified through rapid case ascertainment by 
cancer registries. Patients were interviewed by telephone a 
median of 20 weeks after their diagnosis and provided infor-
mation about demographics, comorbidities, and treatments 
received. Further clinical information was abstracted from 
medical records (available for 80% of patients). Abbreviated 
and proxy versions of the survey were available to patients 
who were unable to complete a full survey or had died by 
the time of contact. The CanCORS study population has 
been shown to be representative of individuals in the United 
States who were diagnosed with lung or colorectal cancer.24 
The study protocol was approved by the institutional review 
board at all participating institutions.
2.2 | Study cohort
Among 5010 patients with lung cancer, we excluded 40 pa-
tients from one study site that did not ascertain survival and 
816 patients with small‐cell lung cancer or missing histologic 
data. Because we assessed racial/ethnic differences, we also 
excluded 904 patients from one study site with >95% non‐
Hispanic white patients, since that site would not inform such 
analyses. The final cohort included 3250 patients (Figure 1).
2.3 | Variables
We grouped variables into three categories: sociode-
mographic characteristics, clinical characteristics, and 
F I G U R E  1  Flow chart of study participants
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treatments. Sociodemographic characteristics included the 
primary variables of interest, self‐reported race/ethnicity, 
annual household income, educational attainment, and insur-
ance type, as well as sex, age (categorized into approximate 
quintiles), marital status, and enrollment in an integrated 
health system (including patients from the integrated health-
care system and Veterans Affairs study sites and patients in 
geographic sites enrolled in integrated health plans). Clinical 
characteristics included a number of self‐reported comor-
bidities,25 smoking status, and stage at diagnosis. Stage was 
assessed based on medical record abstractions or registry 
data when medical records were not available. Treatments 
included patient‐reported receipt of chemotherapy, surgery, 
or radiation. Variables were categorized as in Table 1.
Survival time was measured as days between a patient’s 
diagnosis date and date of death; surviving patients were cen-
sored on the date last presumed to be alive. Date of death 
was obtained from four sources: CanCORS surveys (base-
line or follow‐up, approximately 12 months after diagnosis), 
medical records, a Social Security Death Index match, or a 
National Death Index match. Queries on patient vital status 
from medical records or national death records were stopped 
at all sites by the end of 2012.
Missing data were infrequent (<6% of observations for 
all variables other than income [24%], smoking status [16%], 
and comorbidity [14%]). Missing data for all independent 
variables were imputed using multiple imputation.26 Vital 
status information was complete for all patients in the study 
population. Although some CanCORS studies have included 
information about social supports and baseline quality of life, 
such information was not collected by design for patients who 
were deceased at the time of the baseline survey and were 
not imputed; thus, those variables were not included in the 
analysis.
2.4 | Statistical analysis
We calculated median survival time from diagnosis using 
Kaplan‐Meier estimates and compared differences using log‐
rank tests. We used Cox proportional hazard models to assess 
the relative hazard of death. We tested for violations of the 
proportional hazards assumption by confirming that the log 
hazard‐ratio function for each covariate was constant over 
time. The stage at diagnosis variable interfered with the pro-
portional hazards assumption due to 54 patients from one site 
coded as “local/regional.” In a sensitivity analysis excluding 
those 54 patients, the proportional hazards assumption was 
not violated, and the results did not differ (data not shown).
We first estimated the unadjusted hazard ratio for death 
based on race/ethnicity, income, education, and insurance 
type, as well as age, sex, smoking status, and receipt of care 
in an integrated health system. We then conducted three 
sequential models. The first model included all of these 
sociodemographic variables in a single model. The second 
model adjusted for sociodemographic and clinical character-
istics at diagnosis, including stage, number of comorbidities, 
and smoking status. The third model adjusted for sociodemo-
graphic, clinical, and treatment variables, including receipt of 
surgery, chemotherapy, and/or radiation. Two‐sided P‐values 
<0.05 were considered statistically significant. All models 
adjusted standard errors by clustering for study site. Analyses 
were performed using Stata version 10 (StataCorp, College 
Station, TX).
3 |  RESULTS
Overall, 64% of patients were white, 16% black, 7% Hispanic, 
7% Asian, and 5% other race/ethnicity. Among 2459 patients 
with income data, 27% of patients had incomes <$20 000/y. 
In total, 23% of patients had not completed high school, and 
36% had two or more years of college. Only 1.4% of the 
population was uninsured at the time of diagnosis, 15% were 
insured by Medicaid, dually eligible, or insured by the VA, 
53% of patients had Medicare, and 26% had private/health 
maintenance organization (HMO) insurance.
The median survival time was 470 days after diagnosis. 
Median survival by patient factors is presented in Table 1.
3.1 | Survival differences
3.1.1 | Unadjusted analyses
In unadjusted analyses (Table 2), black patients had a slightly 
greater risk of death than white patients (HR = 1.05; 95% 
CI = 1.00‐1.10; P = 0.05). Hispanic patients tended to have 
a greater risk of death (HR = 1.08; 95% CI = 0.99‐1.19; 
P = 0.08); patients of Asian and other racial/ethnic descent 
did not differ from whites. Patients with lower incomes had 
higher mortality than those with incomes above $60 000 
(HR = 1.34, 95% CI = 1.16‐1.55, P < 0.001 for incomes 
<$20 000; HR = 1.33, 95% CI = 1.18‐1.50, P < 0.001 for 
incomes between $20 000 and $40 000; and HR = 1.13; 95% 
CI = 1.04‐1.23; P = 0.005 for incomes between $40 000 
and $60 000). Patients with less education also had higher 
mortality than patients with some college (HR = 1.29, 95% 
CI = 1.17‐1.42, P < 0.001 for patients who had not com-
pleted high school and HR = 1.13, 95% CI = 1.02‐1.25, 
P = 0.02 for high school graduates). Compared with patients 
who had private/HMO insurance, patients who were unin-
sured (HR = 1.39; 95% CI = 1.07‐1.80; P < 0.02), insured 
by Medicare (HR = 1.29; 95% CI = 1.11‐1.49; P = 0.001), 
or insured by Medicaid/VA/other government insurance 
(HR = 1.32; 95% CI = 1.05‐1.66; P < 0.02) had higher mor-
tality. Mortality was lower for women versus men and for 
younger versus older patients (Table 2).
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T A B L E  1  Characteristics and median survival of patients newly diagnosed with non–small‐cell lung cancer in CanCORS study 2003‐2005, 
N = 3250
N %
Median survivala 
(days) P‐valueb
Race/ethnicity and socioeconomic variables
Race/ethnicity
Non‐Hispanic white 2089 64 494 0.30
Non‐Hispanic black 512 16 476
Hispanic 241 7 464
Asian 226 7 526
Other/multiracial 162 5 504
Missing 20 1 548
Income
>$60 000 454 14 743 0.001
$40‐60 000 391 12 487
$20‐40 000 726 23 391
<$20 000 888 27 409
Missing 791 24 611
Education
Some college or more 1182 36 583 0.001
High school diploma or vocational training 1253 39 459
Non‐high school graduate 732 23 449
Missing 83 2 361
Insurance
Private or HMO 832 26 620 0.001
Uninsured 46 1 290
Medicaid, dual‐eligible, or VA/other 
government
474 15 441
Medicare ± supplemental 1711 53 473
Missing 187 5 446
Sex
Male 1851 57 405 0.001
Female 1399 43 653
Age at diagnosis in years
<60 744 23 570 0.001
60‐66 619 19 590
67‐72 673 20 486
73‐78 665 20 513
>78 549 17 315
Marital status
Married/living with partner 1890 58 475 0.016
Divorced/separated/never married/widowed 1227 38 489
Missing 133 4 874
Integrated health system
Integrated 1360 42 497 0.65
Non‐integrated 1890 58 490
(Continues)
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3.1.2 | Model 1—adjustment for 
sociodemographic variables
In the first model, we adjusted for sociodemographic charac-
teristics (race, income, educational attainment, insurance type, 
sex, age, and marital status) and observed no difference in mor-
tality by race/ethnicity or insurance type (Table 2). Adjusted 
mortality was higher for patients earning <$40 000 yearly 
compared with those earning >$60 000 yearly (HR = 1.20, 95% 
CI = 1.04‐1.38, P = 0.015 for those earning $20 000‐$40 000; 
HR = 1.17, 95% CI = 1.00‐1.36, P = 0.048 for those earn-
ing <$20 000). Patients with less educational attainment had 
higher mortality than those who attended college (HR = 1.16, 
95% CI = 1.06‐1.26, P = 0.001 for those without a high school 
diploma; HR = 1.09, 95% CI = 0.99‐1.20, P = 0.065 for those 
with a high school diploma or vocational training).
N %
Median survivala 
(days) P‐valueb
Clinical characteristics
Stage at diagnosis
Stage 1 818 26 2239 0.001
Stage 2 255 8 950
Stage 3a/NOS 365 11 571
Stage 3b 426 13 358
Stage 4 1167 36 196
Local/regional 54 1 290
Missing 165 5 407
Comorbidities
0 comorbidities 703 22 475 0.001
1 comorbidity 833 26 497
2 comorbidities 593 18 457
3 comorbidities 332 10 391
4 + comorbidities 312 10 336
Missing 477 14 787
Smoking status
Never 306 9 587 0.001
Former 2193 67 393
Current 246 8 705
Missing 505 16 743
Treatments received
Radiation
Yes 1208 37 341 0.001
No 1973 61 669
Missing 69 2 501
Chemotherapy
Yes 1624 50 470 0.001
No 1553 48 574
Missing 73 2 441
Surgery
Yes 1414 44 1489 0.001
No 1778 55 256
Missing 58 1 537
VA, veterans affairs; HMO, health maintenance organization; NOS, not otherwise specified.
aMedian survival from Kaplan‐Meier estimates. 
bBased on log‐rank tests. 
T A B L E  1  (Continued)
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3.1.3 | Model 2—adjustment for 
sociodemographic and clinical variables
In the second model, we adjusted for sociodemographic and 
clinical characteristics, including stage at diagnosis, number 
of comorbidities, and smoking status (Table 2). After this 
adjustment, black patients (HR: 0.87; 95% CI = 0.79‐0.97; 
P = 0.01) and Asian patients (HR: 0.83; 95% CI = 0.75‐0.92; 
P < 0.001) had lower mortality than non‐Hispanic white 
patients. Patients earning $40 000‐$60 000 had simi-
lar mortality as those earning >$60 000. Patients earning 
$20 000‐$40 000 had higher mortality than those earning 
>$60 000 (HR = 1.17; 95% CI = 1.00‐1.37; P = 0.049). The 
difference in mortality by educational attainment was no 
longer statistically significant.
3.1.4 | Model 3—adjustment 
for sociodemographic, clinical, and 
treatment variables
After adjustment for treatments received, including chemo-
therapy, surgery, or radiation, Asian and black patients con-
tinued to have lower mortality compared with non‐Hispanic 
white patients (Table 2). After this adjustment, there was no 
longer any difference in mortality by income. In this fully 
adjusted model, mortality was higher for men versus women, 
patients aged >78 versus <60, patients with advanced‐
stage cancer, and patients with one or more comorbidities. 
Mortality was also higher for patients who did not undergo 
chemotherapy or surgery.
4 |  DISCUSSION
Consistent with previous studies examining disparities in 
care and outcomes for patients with NSCLC, we found that 
race/ethnicity, income, educational status, and insurance 
status were associated with higher mortality among patients 
with NSCLC. However, we found that these differences were 
no longer evident after adjusting for sociodemographic, clini-
cal, and treatment variables.
In unadjusted analysis, black patients had a slightly 
higher risk of mortality compared with white patients, 
but the difference was small (median survival differ-
ences—18 days). This difference was notably smaller than 
the median differences by education (4.5 months), income 
(11 months), and insurance coverage (11 months), which 
likely represent clinically important disparities. The higher 
risk of mortality for black versus white patients was no lon-
ger evident after adjustment for other sociodemographic 
characteristics, including income, education, and insur-
ance. In fact, after adjustment for differences in cancer 
stage and comorbidities, black patients had lower mortality V
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than white patients. These findings differ from studies 
that show higher 5‐year mortality for black and Hispanic 
patients compared with non‐Hispanic white patients.3-5,27 
However, our population differs from these studies in that 
we have a multiregional cohort with a relatively small un-
adjusted difference in mortality between black and white 
patients, and we also had rich, self‐reported data about pa-
tients’ sociodemographic status. Other studies have docu-
mented that black patients with lung cancer have similar 
or better mortality than white patients after adjustment for 
sociodemographic factors28 or in settings with equal‐ac-
cess health systems such as the military.29,30 As a whole, 
this suggests that differences in access to treatment and 
timely diagnosis may play an important role in survival 
differences by race/ethnicity. Asian patients in this study 
had similar mortality as white patients in the unadjusted 
analysis, but had lower mortality than white patients after 
adjustment for clinical factors, including stage. We lacked 
data on molecular markers in our population; however, the 
better survival relative to white patients may reflect the 
higher frequency of favorable EGFR mutations in Asian 
patients with NSCLC.31
Patients earning below $60 000 per year had a 13‐34% 
higher risk of mortality than those earning more than 
$60 000. This difference was diminished in part by ad-
justment for more advanced stage at diagnosis and greater 
comorbidity burden among lower income individuals, and 
further diminished by adjustment for treatment. Previous 
studies have shown that low‐income patients are often di-
agnosed at a later stage than high‐income patients, and late‐
stage disease is a strong predictor of poorer outcomes.32,33 
Patients who have low income may have worse outcomes 
for reasons not captured by stage at diagnosis or number of 
comorbidities. These may include severity of comorbidi-
ties, lack of social support, or even intensity of treatments 
received. Identifying strategies to ensure access to needed 
care in addition to early diagnosis will be important to ad-
dressing income‐related differences in care.
We also observed that patients with less education had 
13‐29% increased risk of mortality than patients with more 
education. This difference was no longer evident after ad-
justment for clinical features at the time of diagnosis. Other 
studies have shown that lower educational attainment pre-
dicts poorer outcomes in patients with NSCLC.34 Our study 
extends such work by assessing patient‐reported educational 
attainment rather than imputing educational attainment by 
geocoded address data at an area‐ or census‐tract level. Our 
study also builds on prior work showing that patients with 
lower levels of education are diagnosed at later stages,35 a 
plausible mechanism leading to higher mortality.
The National Academy of Medicine defines health dis-
parities as differences in care or outcomes that are not due 
to differences in clinical appropriateness or informed patient 
preferences.36 Although we had rich clinical data, we lacked 
information to allow us to fully understand whether the dif-
ferences that persisted after adjustment for stage at diagnosis, 
comorbidities, and treatments received were related to dif-
ferences in access and receipt of high‐quality care or other 
factors like patient preferences and clinical appropriateness. 
However, given the magnitude of survival differences demon-
strated in the unadjusted analysis, these likely represent clin-
ically relevant disparities that are explained by clinical and 
treatment‐related factors.
Our study’s strengths include its diverse and multiregional 
patient population from across the United States as well as 
the rich clinical data from patients, medical records, and 
cancer registries. However, our study has several limitations. 
First, patients were diagnosed more than a decade ago, and 
we cannot be certain that findings would be similar in current 
cohorts, although other evidence suggests that racial/ethnic 
and sociodemographic disparities remain a problem for pa-
tients diagnosed with lung cancer.27,37-39 Second, our patient 
population had a lower rate of uninsurance than the general 
US population. This may reflect the geographic regions we 
studied. It is also possible that patients without insurance 
were less likely to enroll in the study, although we recruited 
patients primarily from population‐based registries, and our 
study cohort was representative of patients in these areas with 
newly diagnosed cancers.24 Lastly, we ascertained treatments 
based on patient report, although other evidence suggests that 
patients can accurately report major cancer treatments such 
as surgery, radiation, and chemotherapy.40,41
In conclusion, we observed higher mortality for NSCLC 
for black versus white patients, patients with non‐private in-
surance, and patient with lower levels of educational attain-
ment and income. The difference between black and white 
patients in survival was no longer evident after adjustment 
for sociodemographic factors, and black patients had better 
outcomes than white patients after adjustment for clinical 
characteristics and treatments received. Clinical character-
istics at the time of diagnosis contributed to higher mortal-
ity for patients with less education and income. Different 
treatments received also contributed to higher mortality for 
low‐income individuals. Our study suggests that disparities 
in NSCLC mortality may be diminished with efforts to en-
sure early diagnosis and effective treatments.
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